Founded in 2001 with the goal of becoming a global axis of antibody therapeutics development—as reflected in our name ISU ABXIS (Anti-Body + aXIS)—we are an innovative biotech company built on 25 years of experience in developing, manufacturing, and commercializing rare disease therapeutics, including Fabry disease.

Building on this foundation, ISU ABXIS is now advancing toward its vision of becoming an "Innovative Biotech" — expanding our pipeline of novel therapeutics through our differentiated antibody platform. In the field of Fabry disease, we remain committed to expanding access to enzyme replacement therapy and supporting the broader clinical community through continued research and education.